![rop-ait-080816-450-bp.jpg](https://www.ibj.com/wp-content/uploads/2019/01/rop-ait-080816-450-bp-300x200.jpg)
AIT meltdown derails huge Marian gift
Five years after pledging an astounding $48 million to help Marian University build a medical school, an Indianapolis businessman has paid only about one-fifth of that amount.
Five years after pledging an astounding $48 million to help Marian University build a medical school, an Indianapolis businessman has paid only about one-fifth of that amount.
Dave Ricks will begin guiding the company during a period of relative calm compared with the trying times John Lechleiter navigated during his eight years at the helm.
Over the last eight years, Eli Lilly relied on a three-decade company veteran to steer it through declining sales and a struggling product pipeline. Now, it’ll rely on another long-time executive for its next chapter.
CEO John Lechleiter said the company's strong R&D pipeline has put it on track to report average annual revenue growth of at least 5 percent through the remainder of the decade.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
Doctors who accept free meals from the pharmaceutical industry are more likely to prescribe certain branded drugs to Medicare patients than generics, according to a study published Monday.
Indianapolis-based Simon Property Group Inc. and Warsaw’s Zimmer Biomet Holdings vaulted back among the top 500 this year, while local oil refiner Calumet Specialty Products Partners plummeted.
One of Indiana’s largest home health care providers, facing allegations that it put patients in immediate jeopardy, has agreed to be acquired by a competing company in a deal that could be worth as much as $3 million.
The competition heated up in the $71.5 billion global diabetes market last year after Indianapolis-based Eli Lilly’s and Boehringer Ingelheim’s Jardiance unexpectedly reduced the risk of heart attacks, strokes and deaths in a study.
The Indianapolis-based drugmaker said Tuesday it has built a robust pipeline of drugs that “has the potential” to launch 20 new products in the 10 years between 2014 and 2023.
The founder of AIT Laboratories, along with his insurance companies and bank, will pay back more than $3 million to employees who bought the company from him six years ago at what the government said was an inflated price.
A federal judge made the award to Lilly’s former executive director of human resources, who quit for health reasons and was later dropped from the company’s extended disability plan.
Deep cuts in Medicare reimbursements and competition from a few huge national chains and walk-in labs are making it tougher for Indianapolis-based AIT and other toxicology labs to compete.
It’s the largest recall in recent years for Cook, which previously had issued four recalls covering more than 400,000 catheters and pressuring monitoring sets in the past two years.
PTS Diagnostics, with about 150 employees in Indianapolis, said Monday it has entered a definitive agreement to be acquired by China-based Sinocare Inc.
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
A Medicare proposal to test new ways of paying for chemotherapy and other drugs given in a doctor's office has sparked a furious battle, and cancer doctors are demanding that the Obama administration scrap the experiment.
Dr. Joseph Tector, who built IU Health’s transplant program into one of the nation’s largest before announcing his departure Friday, is seeking back wages and penalties worth $4.7 million from the hospital system.
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland—on paper—to reduce its tax bill.